Last updated 33 days ago
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
3980 patients around the world
Available in Argentina
Chiesi Farmaceutici S.p.A.
1Research sites
3980Patients around the world
This study is for people with
Chronic obstructive pulmonary disease
Copd
Chronic bronchitis
Requirements for the patient
From 40 Years
All Gender
Medical requirements
StudyPILLAR
SponsorChiesi Farmaceutici S.p.A.
Conditions
CopdChronic bronchitis
Requirements
From 40 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04636814
